Aspen manufacturing is expected to drive the group’s earnings growth in the 2027 financial year, as the company works to replace business lost when a major mRNA production contract ended. Aspen Pharmacare forecasts that manufacturing EBITDA will more than double this year, according to its 2026 integrated report. Sterile Operations Offset Contract Loss In the year to end-June, factory EBITDA…
Tag: JSE
-
Clicks Annual Results Show Turnover Topping R50bn
Clicks annual results show group turnover passing R50bn for the first time, as the health and beauty retailer returned R976m in cashback rewards to loyalty members. Turnover rose 5.4% to R50.4bn in the year to end-August, or about R138m a day. Loyalty and discounts amid cost pressures Clicks ClubCard had 13.1 million active members, who accounted for more than four-fifths…
-
JSE healthcare shares: Aspen leads gains
JSE healthcare shares have advanced this year, with Aspen Pharmacare’s recovery outpacing gains at Netcare and Life Healthcare. However, analysts say sustained growth will depend on manufacturing execution and hospital patient volumes. Aspen has gained about 40% since January and more than 60% over 12 months. At roughly R160 this week, its market value stood near R69bn. Aspen Leads JSE…
-
Dis-Chem Leadership Succession Ends Saltzman Era
Dis-Chem co-founder Ivan Saltzman has resigned from the pharmacy retailer’s board after 48 years. His departure ends the founding family’s formal representation in the company’s boardroom. The JSE-listed healthcare group said Saltzman stepped down as a non-executive director with effect from 23 July 2026. He retired as an executive director at the end of June. He then briefly served in…
-
Life Healthcare Expansion Plans Add Beds And Specialists
Private hospital group Life Healthcare is moving forward with strategic growth initiatives. The JSE-listed company intends to expand capacity, open a new hospital, and recruit more specialists. These Life Healthcare expansion plans aim to significantly boost occupancy rates across all its medical facilities. Strategic Asset Growth And Infrastructure Investments The company will continue to grow its underlying asset base in…
-
Netcare CEO Transition: Melanie Da Costa Named Successor
Netcare has confirmed a high-profile leadership handover that will reshape the top team at one of South Africa’s biggest private healthcare groups. The JSE-listed company has appointed long-serving executive Melanie Da Costa as its next chief executive officer, with a phased transition that runs through 2026 and into 2027. Da Costa is currently Executive Director for Strategy and Health Policy.…
-
AfroCentric Results Show Revenue Surged Significantly
AfroCentric Investment Corporation has released its financial results for the year ending December. The JSE-listed healthcare giant reported a massive spike in revenue. However, the group also faced a significant basic loss. This was primarily due to heavy asset impairments and strategic business disposals. Massive Revenue Growth For AfroCentric The group’s continuing operations showed exceptional top-line growth. Total revenue climbed…
-
Digitisation Drives Netcare’s Growth with a 20.7% in HEPS
Hospital Group Netcare has delivered a robust set of full-year earnings for the year ended 30 September 2025. The group reported a significant 20.7% surge in adjusted headline earnings per share (HEPS) to 137.2 cents, underpinned by resilient demand for private healthcare and the successful execution of its digitisation strategy. Indeed, digitisation is driving Netcare’s growth, contributing significantly to these…
-
AfroCentric’s JSE Collapse Fuels a New Healthcare Empire
As insurance giant Sanlam tightens its grip on health-fin services specialist AfroCentric, the line between public company and private control has all but vanished. What remains is a powerful lesson in strategic patience. It reveals how corporations (or businesses) can methodically turn market neglect into a corporate opportunity. While AfroCentric still technically trades on the JSE, its story is no…
-
Adcock Ingram Delisting After Natco Acquisition
Pharmaceutical giant Adcock Ingram has confirmed its delisting from the Johannesburg Stock Exchange (JSE) on 11 November 2025. The move marks the end of its 17-year run as a public company. This follows the finalisation of a R4.2 billion acquisition scheme by the Indian-based Natco Pharma. The company announced that it had fulfilled or waived all conditions precedent for the…
-
Clicks Digital Push to Enhance Online Delivery Services
Healthcare and beauty retailer Clicks is embarking on a significant overhaul of its e-commerce platform. Its digital push aims to capitalise on growing home delivery demand and significantly improve customer convenience. The move comes as the retailer acknowledged that its online performance has been “sluggish”. This sluggishness is due to limited delivery options and lead times, despite online sales growing…
-
Adcock Ingram Takeover Gets Green Light from Shareholders
Shareholders in Adcock Ingram, the renowned South African pharmaceutical company, have decisively approved a takeover offer from Indian drugmaker Natco Pharma. This paves the way for the company to delist from the Johannesburg Stock Exchange (JSE) after 16 years. At a general meeting last week, shareholders voted 98.66% of shares in favour of the offer. The deal will see Natco…